Newsfile Corp
18 May 2026, 04:47 UTC · 3d ago
Source · https://www.newsfilecorp.com/release/297778/PBH-ALERT-Ongoing-Investigation-Into-Prestige-Consumer-Healthcare-Inc.-Contact-Levi-Korsinsky
Read source
Story key points
3 claims · impact-rated
Prestige Consumer Healthcare missed its Q4 FY2026 guidance across all three key metrics, reporting adjusted gross margin of 55.4% vs. 57% projected, free cash flow of $228M vs. $245M+ projected, and adjusted diluted EPS of $4.38 vs. $4.54 projected. — A broad miss on margin, cash flow, and earnings guidance directly undermines investor confidence in the company's forecasting and near-term financial trajectory, triggering sharp sell-offs.
-0.85Prestige Consumer Healthcare completed a $150 million acquisition of Australian skin-care firm LaCorium that was not disclosed or discussed during the prior Q3 earnings call or included in forward guidance. — Failing to communicate a major capital allocation event prior to execution erodes management credibility, introduces integration and cash flow risks, and raises severe transparency concerns.
-0.75A law firm has commenced a federal securities law investigation into Prestige Consumer Healthcare concerning the missed projections and undisclosed acquisition. — A securities investigation introduces legal risk, potential financial liabilities, and management distraction, weighing on the stock's risk profile even if the litigation outcome is uncertain.
Search tags
Impact vectors
3 dimensions · 9 clusters
Market reaction
0 bid · 0 offered
No stock impact ranking available yet.
No stock impact ranking available yet.
Ticker attribution
Model heads
The company is under investigation for potential securities law violations after missing financial projections and failing to disclose an acquisition.
The company is the subject of an investigation by a securities litigation firm following shareholder losses.
The company is being investigated for fraud on behalf of shareholders.
No ticker relationship head found.
